stockrowProfound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.
- Revenue
- +85.9%
- EPS
- +18.8%
- Free cash flow
- +47.9%
- Total debt
- +0.71%
Quarter to September 2026, against a year earlier
Follow PROF
Alert me
Profound Medical (PROF) EV/Sales
As of 5 November 2026, Profound Medical (PROF) trades at a EV/Sales of 9.6×. Over the past ten years it has ranged from 0.0× (December 2019) to 55.3× (February 2021); the current reading is higher than 19% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 11.6× | (8.51%) |
| FY2024 | 12.7× | (38.71%) |
| FY2023 | 20.7× | (27.39%) |
| FY2022 | 28.6× | 19.68% |
| FY2021 | 23.9× | (36.23%) |
| FY2020 | 37.4× | 24.54% |
| FY2019 | 30.1× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 7.9× | (29.84%) |
| Jun 2026 | 11.3× | 9.85% |
| Mar 2026 | 10.3× | (11.36%) |
| Dec 2025 | 11.6× | 26.59% |
| 27 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LAB Standard BioTools Inc. compare | −2.5× |
| RXST RxSight, Inc. compare | −0.4× |
| TMCI Treace Medical Concepts, Inc. compare | 1.4× |
| INFU InfuSystems Holdings, Inc. compare | 2.0× |
| ELMD Electromed, Inc. compare | 2.7× |
| TLSI TriSalus Life Sciences, Inc. compare | 4.3× |
| CLPT ClearPoint Neuro, Inc. compare | 6.0× |
| PROF Profound Medical | 9.6× |
| QSI Quantum-Si Incorporated compare | 121× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)